The suprachoroidal space

Drugs precisely delivered by suprachoroidal injection with access to the choroid and the retina where the diseases present. 



Diabetic Macular Edema (DME)

Diabetic Macular Edema (DME) is an accumulation of fluid in the macula caused by leaky blood vessels as a consequence of diabetes mellitus. It is defined as retinal thickening within 2 disc diameters of the macula center. DME is the most common complication of Diabetes in patients with Diabetic Retinopathy (DR). DR affects more than 150 million people worldwide.1 It may cause images to appear blurry or wavy and colors that seem “washed out”.

1. Gupta N, Mansoor S, Sharma A, et al. Diabetic retinopathy and VEGF. Open Ophthalmol J. 2013;7:4-10.

Diabetic Macular Edema Phase 2: TYBEE Trial

  • Controlled, masked, randomized study of combination suprachoroidal CLS-TA intravitreal Eylea vs. intravitreal Eylea alone
  • Evaluation at Month 6; treatment is based on PRN criteria from Month 3
  • Primary outcome measure is comparison of mean change from baseline in BCVA at 24 weeks between the combination arm and the control arm. The study was powered and designed to show that the mean change in BCVA is not different between the two arms.

Combination arm: Intravitreal Eylea suprachoroidal CLS-TA (n=36)

Tybee chart

Any additional treatment based on as needed criteria at Week 16 and Week 20 will be intravitreal Eylea

Join our team at Clearside

Learn more about career opportunities and benefits at Clearside Biomedical.